Comparing AC Immune (ACIU) and The Competition
AC Immune (NASDAQ: ACIU) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare AC Immune to similar businesses based on the strength of its risk, dividends, profitability, valuation, earnings, institutional ownership and analyst recommendations.
This table compares AC Immune and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AC Immune Competitors||-4,588.14%||-473.01%||-43.24%|
This is a breakdown of current recommendations for AC Immune and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AC Immune Competitors||561||2493||6755||134||2.65|
AC Immune currently has a consensus price target of $18.00, suggesting a potential upside of 38.04%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.15%. Given AC Immune’s stronger consensus rating and higher probable upside, equities research analysts clearly believe AC Immune is more favorable than its peers.
Earnings & Valuation
This table compares AC Immune and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AC Immune||$23.55 million||-$7.20 million||-19.18|
|AC Immune Competitors||$217.40 million||-$39.57 million||-61.73|
AC Immune’s peers have higher revenue, but lower earnings than AC Immune. AC Immune is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
17.1% of AC Immune shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
AC Immune beats its peers on 8 of the 12 factors compared.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.